International Society for Heart and Lung Transplantation ISHLT

Currently, MMF is approved for use in kidney, liver, and heart transplants. A recent analysis of 5599 patients in the Joint International Society for Heart and Lung Transplantation (ISHLT) and UNOS Thoracic Registry showed a statistically signihcant survival advantage for MMF compared with azathioprine (1 year, 96% versus 93% 3 years, 91% versus 86%). Efficacy has been demonstrated in combination with both CSA and TAC. 

LT is the best therapeutic option for patients with IPF with life-threatening disease (208-210). Since no medical therapies have been proven to influence survival in IPF, IPF patients should be referred to LT centers at the time of diagnosis (provided no contraindications exist). The decision to list for LT is best made by the local transplant team members, who are familiar with local waiting times. Either single (SLT) or bilateral sequential lung transplantation (BSLT) can be performed (208,209,211). Data from the International Society for Heart and Lung Transplantation (ISHLT) Registry reported that 19% of >17,000 LTs... 

---